PharmaCyte Biotech Inc (PMCB)

[Gmc2020]

Nuvilex (NVLX): Don't Be Fooled By Quiet Trading

It's been a rather quiet week on the trading front for Nuvilex (NVLX), but it's anything but quiet on the corporate front.

It's been a bit quiet all the way around, with the microcap world in a kind of sideways, low volume mode.

So, a bit boring over the past week. But, looking back over the past year, I'd say NVLX has been anything but boring.

Consider little NVLX was $.05 just over a year ago. It only rocketed up to 12 times it's price, then got cut in half from the top. Net result, the stock is just under 5 times the price it was a year ago.

I'd say that's anything but boring. In the course of the year, there was lots of controversy, and all the detractors were proven wrong. I hope microcap investors are beginning to learn the louder the voices calling a perfectly legitimate company a scam, the more likely short sellers are desperately trying to get misinformation out through the internet, and scare you into selling your shares back to them for their profits.

So, while it hasn't been a volatile week on the price front, it's been an informative week on the corporate front, and shareholders who have a longer term view should recognize there is another meteoric run for this stock in the not too distant future- In my view, it's just a question of when.

Since last week, there have been 6 news items on NVLX. The first recounts NVLX's plan, working with world renown cancer expert Dr. Daniel Von Hoff, to use early studies to get into an accelerated approval status with the FDA for their Pancreatic Cancer Therapy.

Secondly, in the past week NVLX has announced plans to do a recorded interview at the American Society of Clinical Oncology which runs through next week. COO Dr. Gerry Crabtree will be discussing the company's technology with a group of cancer experts.

On the market side, NVLX is presenting at institutionally sponsored investors conferences on both the east and west coast. Investors can take this as an indication the company is at an inflection point where its fundamental progress will make NVLX company worth looking at by the big boys.

Lastly, and probably most importantly, NVLX announced a change of plans for future capital raising activities to the positive for shareholders.

NVLX has abandoned its agreement with Chicago Based Lincoln Park on $27 million in financing, and has entered into an agreement with Chardan Capital Markets to raise up to $50 Million in at "At Market" banking arrangement.

In my view, this is the least toxic and most flexible way to raise capital. It allows the company, at its sole discretion, to raise equity capital at the current market price, which is the least dilutive method of raising equity.

NVLX will also have the flexibility to raise capital in small or large amounts, depending on need and price and liquidity in the open market.

NVLX has consistently demonstrated a policy of protecting shareholder value. The last two financing were done at fixed prices "above the market"- that's unheard of for a microcap like this.

I believe NVLX has raised about $6 million in the past year, but will now have the ability to raise another $50 million going forward.

I'll be attending their presentation at the LD Micro Conference in LA next week, so I hope to have some feedback for everybody.

In the meantime, NVLX, up six times the price over the last year, is making all the right moves on the corporate front to commercialize their technology.

As I've pointed out in past editions, a stock like NVLX is going to make one or two meteoric and breathtaking runs a year based on market conditions and company developments.

We saw it last week with LiveDeal (LIVE)- the stock went from 500,000 shares last Thursday to 24 million the next day- up 80%- for no apparent reason. I know the reason- it was a short squeeze. Short sellers were forced to cover, causing the stock to rocket on huge volume.

These are the moves you position yourself for in a stock like Nuvilex (NVLX) at times like this. The company is making all the right moves to get its technology into the FDA Approval process.

This was the second giant run for LiveDeal (LIVE). Will you be properly positioned to make a lot of money when Nuvilex (NVLX) makes its next run?

The opportunity is there today.

Text the word PROFITS to 86677 for instant delivery of the OTC Journal to your smart phone.

Email is not as reliable as it used to be. This will insure you receive each edition promptly.

MarketByte LLC currently has no shares of Nuvilex, and has no contractual obligation to cover the company. Therefore, there are no conflicts of interest.


Home Page: www.otcjournal.com
Email Questions or Comments To: [e-mail]


DISCLAIMER

The OTC Journal Newsletter is an electronic publication committed to providing our readers with useful information on publicly traded companies. The Newsletter contracts with publicly traded companies or third parties and receives compensation from them as payment for publishing information and opinions about the company and the trading market for their securities. Principals of the Newsletter may also purchase or sell securities of the companies in the open market from time to time. The positions, if any, that the Newsletter or its principals presently maintain in the securities of the companies are disclosed here (click here) and should be considered in making an investment decision regarding these companies securities. The Newsletter and its principals reserve the right to acquire additional shares or liquidate some or all of the positions they may hold in the issuer's securities at any time in the future without further notice. These publications should not be considered to be independent publications concerning the company.

All statements and opinions expressed herein are those of the editors and are subject to change without notice. The Newsletter maintains editorial control over its publications and the companies profiled therein do not have any editorial rights concerning the information published about them. While we believe all sources of information provided by us and contained in our publication to be accurate and reliable, we cannot and do not guarantee the accuracy of information we received from third parties. MarketByte LLC currently has no shares of Nuvilex, and no contractual obligation to cover the company. Therefore, there are no conflicts of interest.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.finra.org. We also recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.